Frequently Asked Questions
LogiX Biosciences targets the epithelium and resolving quickly allergy and non-allergy caused sinusitis.
LGX 242 is pre-clinical with a post toxicology proof of concept planned in collaboration with the Mayo Clinic
Our second area of drug development is that of multi-drug resistant bacteria. This drug is in invitro testing
Our second area of drug development is that of multi-drug resistant bacteria. This drug is in invitro testing
Our second area of drug development is that of multi-drug resistant bacteria. This drug is in invitro testing
Our second area of drug development is that of multi-drug resistant bacteria. This drug is in invitro testing
